Incyte (NASDAQ:INCY) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

FDA updates talazoparib and enzalutamide labeling, confirming survival benefits for HRR-mutated mCRPC, while excluding ...

FDA approves updated labeling for Talzenna plus Xtandi in men with HRR gene-mutated metastatic prostate cancer, showing a ...

This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV.

Gilead’s Yeztugo will offer an alternative to treatments such as daily pills and every-other-month injections.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The Food and Drug Administration (FDA) has approved Harliku ™ (nitisinone) for the reduction of urine homogentisic acid (HGA) in adult patients with alkaptonuria.

The U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie Inc’s (NYSE:ABBV) Mavyret ...

The approval comes more than three years after cabotegravir, which is offered by ViiV Healthcare under the name Apretude, was ...

When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. | After ...

Data from the Phase 3, multicenter, single-arm prospective study evaluating the safety and efficacy of Mavyret eight-week treatment in adults with acute HCV infection supported the label expansion.